Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (ticker: CLDI) is a clinical-stage biopharmaceutical company developing stem cell-based platforms to deliver oncolytic viruses as targeted cancer immunotherapies, operating in the oncology biotechnology sector. The company entered public markets through a de-SPAC merger with First Light Acquisition Group, a blank-check vehicle that completed its IPO in 2021 with First Light Acquisition Group LLC serving as sponsor. At the time of its May 2023 Form 10-Q filing, the transaction remained pending; the merger subsequently closed in September 2023, with the combined company trading on NYSE American under CLDI. Sign up at SpacDesk for full sponsor profiles, filing timelines, and SPAC transaction data on CLDI and thousands of other deals.